Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 9/20 | 0.38 |
| ▸ | NPY1R | P25929 | 6/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.37 |
| ▸ | NPY2R | P49146 | 3/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13707032 | 0.94 | SIRT5 (0.47) | SIRT5FOLH1GNPATNPY4RNPY1R | |
| SCHEMBL30248962 | 0.87 | FOLH1 (0.55) | SIRT5FOLH1GNPATNPY4RNPY1R | |
| SCHEMBL13624779 | 0.87 | FOLH1 (0.55) | SIRT5FOLH1GNPATNPY4RNPY1R | |
| SCHEMBL13701341 | 0.84 | SIRT5 (0.63) | SIRT5FOLH1GNPATNPY4RNPY1R | |
| SCHEMBL13701342 | 0.84 | SIRT5 (0.57) | SIRT5FOLH1GNPATNPY4RNPY1R | |
| SCHEMBL15856928 | 0.81 | SIRT5 (0.54) | SIRT5FOLH1GNPATNPY4RNPY1R | |
| SCHEMBL13166808 | 0.81 | SIRT5 (0.59) | SIRT5FOLH1GNPATNPY4RNPY1R | |
| SCHEMBL30463273 | 0.81 | SIRT5 (0.59) | SIRT5FOLH1GNPATNPY4RNPY1R | |
| SCHEMBL29655002 | 0.81 | GNPAT (0.53) | SIRT5FOLH1GNPATNPY4RNPY1R | |
| SCHEMBL29454444 | 0.81 | GNPAT (0.53) | SIRT5FOLH1GNPATNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622446-B2 | Polypeptides, derivatives and uses thereof | THE OPEN UNIVERSITY (GB) | 2009-11-24 | — | — | US | disclosed |
| US-20090227520-A1 | Treatment methods using peptides related to amyloid precursor protein | THE OPEN UNIVERSITY (GB) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227520-A1 | Treatment methods using peptides related to amyloid precursor protein | APP, IAPP, BACE1 | SIRT5 2977/4885FOLH1 1275/4885GNPAT 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.